Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Apr;34(4):466–469. doi: 10.1136/gut.34.4.466

Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.

G Bianchi Porro 1, F Parente 1, M Lazzaroni 1
PMCID: PMC1374304  PMID: 8491391

Abstract

Thirty two patients with Helicobacter pylori positive duodenal ulcers resistant to treatment were randomly assigned to 4 weeks' treatment with sucralphate 4 g/day or colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14. After 4 weeks, patients with unhealed ulcers were crossed over to the other form of treatment for a further 4 week period. Patients with healed ulcers were followed up for 1 year without maintenance therapy with clinical and endoscopic investigations 3, 6, and 12 months after healing. Complete healing rates at 4 weeks were 88% (15 of 17) in the colloidal bismuth subcitrate plus antibiotics group and 40% (six of 15) in the sucralphate group (p < 0.05). After cross over, overall healing rates were 88% (22 of 25) and 47% (eight of 17), respectively (p < 0.05). H pylori eradication occurred in 83% of patients treated with the triple therapy. Cumulative relapse rates at 12 months were 12% (two of 17) in patients in whom H pylori had been eradicated and 100% (10 of 10) in those with persistent infection after short term therapy (p < 0.05). These results show that a colloidal bismuth subcitrate plus antibiotics regimen is highly effective in the short term treatment of resistant duodenal ulcers and that H pylori eradication can change the natural tendency to early recurrence of these ulcers.

Full text

PDF
466

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bardhan K. D., Naesdal J., Bianchi Porro G., Petrillo M., Lazzaroni M., Hinchliffe R. F., Thompson M., Morris P., Daly M. J., Carroll N. J. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. Gut. 1991 Apr;32(4):435–438. doi: 10.1136/gut.32.4.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bardhan K. D. Refractory duodenal ulcer. Gut. 1984 Jul;25(7):711–717. doi: 10.1136/gut.25.7.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bayerdörffer E., Pirlet T., Sommer A., Kasper G., Ottenjann R. Ofloxacin in der Therapie "resistenter" Ulcera duodeni. Eine Pilotstudie. Z Gastroenterol. 1988 Mar;26(3):155–159. [PubMed] [Google Scholar]
  4. Bianchi Porro G., Parente F., Lazzaroni M. Tripotassium dicitrato bismuthate (TDB) versus two different dosages of cimetidine in the treatment of resistant duodenal ulcers. Gut. 1987 Jul;28(7):907–911. doi: 10.1136/gut.28.7.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brunner G., Creutzfeldt W., Harke U., Lamberts R. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion. 1988;39(2):80–90. doi: 10.1159/000199610. [DOI] [PubMed] [Google Scholar]
  6. George L. L., Borody T. J., Andrews P., Devine M., Moore-Jones D., Walton M., Brandl S. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust. 1990 Aug 6;153(3):145–149. doi: 10.5694/j.1326-5377.1990.tb136833.x. [DOI] [PubMed] [Google Scholar]
  7. Graham D. Y., Lew G. M., Evans D. G., Evans D. J., Jr, Klein P. D. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15;115(4):266–269. doi: 10.7326/0003-4819-115-4-266. [DOI] [PubMed] [Google Scholar]
  8. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  9. Guerreiro A. S., Neves B. C., Quina M. G. Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. Aliment Pharmacol Ther. 1990 Jun;4(3):309–313. doi: 10.1111/j.1365-2036.1990.tb00476.x. [DOI] [PubMed] [Google Scholar]
  10. Lam S. K., Lee N. W., Koo J., Hui W. M., Fok K. H., Ng M. Randomised crossover trial of tripotassium dicitrato bismuthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut. 1984 Jul;25(7):703–706. doi: 10.1136/gut.25.7.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  12. Quintero Diaz M., Sotto Escobar A. Metronidazole versus cimetidine in treatment of gastroduodenal ulcer. Lancet. 1986 Apr 19;1(8486):907–907. doi: 10.1016/s0140-6736(86)91006-8. [DOI] [PubMed] [Google Scholar]
  13. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  14. Satoh H., Guth P. H., Grossman M. I. Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics. Gastroenterology. 1983 Mar;84(3):483–489. [PubMed] [Google Scholar]
  15. Tytgat G. N., Lamers C. B., Hameeteman W., Jansen J. M., Wilson J. A. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther. 1987 Feb;1(1):31–38. doi: 10.1111/j.1365-2036.1987.tb00603.x. [DOI] [PubMed] [Google Scholar]
  16. Wagner S., Gebel M., Haruma K., Bär W., Lange P., Freise J., Gladziwa U., Schmidt F. W. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori. Gut. 1992 Feb;33(2):179–183. doi: 10.1136/gut.33.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Whittingham S., Naselli G., McNeilage L. J., Coppel R. L., Sturgess A. D. Serological diagnosis of primary Sjögren's syndrome by means of human recombinant La (SS-B) as nuclear antigen. Lancet. 1987 Jul 4;2(8549):1–3. [PubMed] [Google Scholar]
  18. Zheng Z. T., Wang Z. Y., Chu Y. X., Li Y. N., Li Q. F., Lin S. R., Xu Z. M. Double-blind short-term trial of furazolidone in peptic ulcer. Lancet. 1985 May 4;1(8436):1048–1049. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES